NKGen Biotech to Present Updated Phase 1 Data on Snk02 Allogeneic Nk Cell Therapy in Solid Tumors at the 6TH Annual Allogeneic Cell Therapies Summit 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.